Adenosine Deaminase-Severe Combined Immunodeficiency Global Market Report 2025

Description

Adenosine deaminase-severe combined immunodeficiency (ADA-SCID) is a rare genetic disorder caused by a deficiency of the enzyme adenosine deaminase, resulting in the toxic accumulation of metabolites that hinder immune cell development. Understanding ADA-SCID is crucial for early diagnosis and management to prevent life-threatening infections and complications.

The primary treatment options for ADA-SCID include enzyme replacement therapy (ERT), gene therapy, stem cell transplantation, and supportive care. ERT involves administering synthetic or recombinant enzymes to compensate for the deficient or absent enzyme in individuals with genetic disorders. These therapies are delivered through various routes, including intravenous, subcutaneous, and oral administration. Designed for both pediatric and adult patients, they are distributed through hospital, retail, and online pharmacies. Key end-users include hospitals, specialty clinics, research institutes, and other healthcare facilities.

The adenosine deaminase-severe combined immunodeficiency market research report is one of a series of new reports from The Business Research Company that provides adenosine deaminase-severe combined immunodeficiency market statistics, including the adenosine deaminase-severe combined immunodeficiency industry global market size, regional shares, competitors with the adenosine deaminase-severe combined immunodeficiency market share, detailed adenosine deaminase-severe combined immunodeficiency market segments, market trends, and opportunities, and any further data you may need to thrive in the adenosine deaminase-severe combined immunodeficiency industry. This adenosine deaminase-severe combined immunodeficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The adenosine deaminase-severe combined immunodeficiency market size has grown strongly in recent years. It will grow from $5.57 billion in 2024 to $5.95 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to the rising prevalence of severe combined immunodeficiency, an increasing incidence of primary immunodeficiencies (PID), a growing burden of immunodeficiency disorders, higher healthcare investments, and greater awareness of immunodeficiencies.

The adenosine deaminase-severe combined immunodeficiency market size is expected to see strong growth in the next few years. It will grow to $7.70 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period can be driven by the rising prevalence of genetic disorders, increased use of bone marrow transplantation, growing demand for non-conditioned stem cell transplantation, a higher prevalence of ADA deficiency, and a rising number of adenosine deaminase deficiency (PDA) cases. Key trends in this period include technological advancements, the adoption of gene therapy, government initiatives, advancements in genetic testing, and progress in biotechnology.

The increasing prevalence of genetic disorders is expected to drive the growth of the adenosine deaminase-severe combined immunodeficiency (ADA-SCID) market. Genetic disorders result from abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. Factors such as advancements in diagnostic technologies, greater awareness, higher parental age, environmental influences, and population growth contribute to the rising prevalence of genetic conditions. In particular, the increasing occurrence of genetic disorders, including ADA-SCID, is fueling the demand for advanced diagnostic techniques and targeted treatments. For example, in December 2022, a report published by the Department of Health & Social Care (DHSC), a UK-based government department, revealed that as of October 2022, approximately 33,000 whole genome equivalents had been sequenced, with an average diagnostic yield of 32%, rising to 61% in specific conditions. Consequently, the growing prevalence of genetic disorders is propelling the expansion of the ADA-SCID market.

Leading companies in the ADA-SCID market are prioritizing the development of innovative treatments, such as gene therapy, to improve patient outcomes, enhance survival rates, and address the underlying genetic causes of the disorder using advanced medical technologies. Gene therapy for ADA-SCID aims to correct the genetic defect by introducing a functional copy of the ADA gene, potentially offering a long-term cure for this rare and life-threatening immune condition. For instance, in May 2022, Danaher Corporation, a US-based life sciences and diagnostics company, joined the Bespoke Gene Therapy Consortium (BGTC) as part of the Accelerating Medicines Partnership (AMP) program. This initiative, in collaboration with the U.S. Food and Drug Administration (FDA), the National Institutes of Health (NIH), pharmaceutical companies, and non-profit organizations, seeks to advance customized gene therapies for rare diseases and streamline their development. This collaboration is particularly important as it addresses the challenges of traditional drug development for rare diseases, which often receive limited commercial interest due to their low prevalence.

In January 2024, Kyowa Kirin Co., Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics plc. for an undisclosed amount. This acquisition enhances Kyowa Kirin's focus on developing innovative treatments for rare and complex diseases by leveraging Orchard Therapeutics' expertise in gene therapy. Orchard Therapeutics plc, a UK-based company, specializes in creating gene therapies for rare genetic disorders.

Major players in the adenosine deaminase-severe combined immunodeficiency market are Novartis AG, GlaxoSmithKline plc (GSK), Astellas Pharma, Orient EuroPharma, Charles River Laboratories, Chiesi Farmaceutici S.p.A., Spark Therapeutics, Rocket Pharmaceuticals, Bluebird Bio, Ospedale San Raffaele (OSR), Oxford Biomedica PLC, Teijin Pharma, Leadiant Biosciences, Orchard Therapeutics PLC, Fondazione Telethon, Mustang Bio Inc., Sigma-Tau Pharmaceuticals, Shenzhen Geno-Immune Medical Institute, ENZON Pharmaceuticals, and QED Bioscience Inc.

North America was the largest region in the adenosine deaminase-severe combined immunodeficiency market in 2024. The regions covered in adenosine deaminase-severe combined immunodeficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adenosine deaminase-severe combined immunodeficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adenosine deaminase-severe combined immunodeficiency market consists of revenues earned by entities by providing services such as diagnosis and genetic testing, therapy services, and consultation & genetic counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The adenosine deaminase-severe combined immunodeficiency market also includes sales of diagnostic tools, supportive therapies, and genetic testing kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adenosine Deaminase-Severe Combined Immunodeficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adenosine deaminase-severe combined immunodeficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adenosine deaminase-severe combined immunodeficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adenosine deaminase-severe combined immunodeficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment Type: Enzyme Replacement Therapy (ERT); Gene Therapy; Stem Cell Transplantation; Supportive Care Treatments
2) By Route of Administration: Intravenous; Subcutaneous; Oral
3) By Age Group: Pediatric (Infants and Children); Adults
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Others End-Users
Subsegments:
1) By Enzyme Replacement Therapy (ERT): Adenosine Deaminase Enzyme Replacement; Pegylated Erythropoietin (PEG-EPO)
2) By Gene Therapy: Autologous Stem Cell-Based Gene Therapy; Viral Vector-Mediated Gene Therapy
3) By Stem Cell Transplantation: HLA-Matched Bone Marrow Transplant; Umbilical Cord Blood Transplant
4) By Supportive Care Treatments: Antimicrobial Therapy; Immune System Support; Nutritional Support
Companies Mentioned: Novartis AG; GlaxoSmithKline plc (GSK); Astellas Pharma; Orient EuroPharma; Charles River Laboratories
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33951

1. Executive Summary

2. Adenosine Deaminase-Severe Combined Immunodeficiency Market Characteristics

3. Adenosine Deaminase-Severe Combined Immunodeficiency Market Trends And Strategies

4. Adenosine Deaminase-Severe Combined Immunodeficiency Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Adenosine Deaminase-Severe Combined Immunodeficiency Growth Analysis And Strategic Analysis Framework

5.1. Global Adenosine Deaminase-Severe Combined Immunodeficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market Growth Rate Analysis
5.4. Global Adenosine Deaminase-Severe Combined Immunodeficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Adenosine Deaminase-Severe Combined Immunodeficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Adenosine Deaminase-Severe Combined Immunodeficiency Total Addressable Market (TAM)

6. Adenosine Deaminase-Severe Combined Immunodeficiency Market Segmentation

6.1. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme Replacement Therapy (ERT)
Gene Therapy
Stem Cell Transplantation
Supportive Care Treatments
6.2. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous
Subcutaneous
Oral
6.3. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric (Infants and Children)
Adults
6.4. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Research Institutes
Others End-User
6.6. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Sub-Segmentation Of Enzyme Replacement Therapy (ERT), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adenosine Deaminase Enzyme Replacement
Pegylated Erythropoietin (PEG-EPO)
6.7. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Autologous Stem Cell-Based Gene Therapy
Viral Vector-Mediated Gene Therapy
6.8. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Sub-Segmentation Of Stem Cell Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
HLA-Matched Bone Marrow Transplant
Umbilical Cord Blood Transplant
6.9. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Sub-Segmentation Of Supportive Care Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antimicrobial Therapy
Immune System Support
Nutritional Support

7. Adenosine Deaminase-Severe Combined Immunodeficiency Market Regional And Country Analysis

7.1. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market

8.1. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Adenosine Deaminase-Severe Combined Immunodeficiency Market

9.1. China Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
9.2. China Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Adenosine Deaminase-Severe Combined Immunodeficiency Market

10.1. India Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market

11.1. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
11.2. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market

12.1. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market

13.1. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market

14.1. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
14.2. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market

15.1. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
15.2. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market

16.1. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market

17.1. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Adenosine Deaminase-Severe Combined Immunodeficiency Market

18.1. France Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market

19.1. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market

20.1. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market

21.1. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
21.2. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market

22.1. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market

23.1. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
23.2. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market

24.1. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
24.2. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market

25.1. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
25.2. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market

26.1. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
26.2. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market

27.1. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market

28.1. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
28.2. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market

29.1. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market Overview
29.2. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Adenosine Deaminase-Severe Combined Immunodeficiency Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Landscape And Company Profiles

30.1. Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Landscape
30.2. Adenosine Deaminase-Severe Combined Immunodeficiency Market Company Profiles
- 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. GlaxoSmithKline plc (GSK) Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Astellas Pharma Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Orient EuroPharma Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Charles River Laboratories Overview, Products and Services, Strategy and Financial Analysis

31. Adenosine Deaminase-Severe Combined Immunodeficiency Market Other Major And Innovative Companies

31.1. Chiesi Farmaceutici S.p.A.
31.2. Spark Therapeutics
31.3. Rocket Pharmaceuticals
31.4. Bluebird Bio
31.5. Ospedale San Raffaele (OSR)
31.6. Oxford Biomedica PLC
31.7. Teijin Pharma
31.8. Leadiant Biosciences
31.9. Orchard Therapeutics PLC
31.10. Fondazione Telethon
31.11. Mustang Bio Inc
31.12. Sigma-Tau Pharmaceuticals
31.13. Shenzhen Geno-Immune Medical Institute
31.14. ENZON Pharmaceuticals
31.15. QED Bioscience Inc.

32. Global Adenosine Deaminase-Severe Combined Immunodeficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adenosine Deaminase-Severe Combined Immunodeficiency Market

34. Recent Developments In The Adenosine Deaminase-Severe Combined Immunodeficiency Market

35. Adenosine Deaminase-Severe Combined Immunodeficiency Market High Potential Countries, Segments and Strategies

35.1 Adenosine Deaminase-Severe Combined Immunodeficiency Market In 2029 - Countries Offering Most New Opportunities
35.2 Adenosine Deaminase-Severe Combined Immunodeficiency Market In 2029 - Segments Offering Most New Opportunities
35.3 Adenosine Deaminase-Severe Combined Immunodeficiency Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer